Brief: Heron Therapeutics Announces U.S. FDA Approval Of Aponvie™ (Htx-019) For The Prevention Of Postoperative Nausea And Vomiting (Ponv)
16/09/2022 19:52
Sept 16 (Reuters) - Heron Therapeutics :
* HERON THERAPEUTICS ANNOUNCES U.S. FDA APPROVAL OF APONVIE™
(HTX-019) FOR THE PREVENTION OF POSTOPERATIVE NAUSEA AND
VOMITING (PONV)
Source text for Eikon: ID:nPn9kCFBya
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Heron Therapeutics
See all newsHeron Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Heron Therapeutics Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: U.S. District Court Issues Decision Regarding CINVANTI Patents
Heron Therapeutics' Q1 revenue falls as oncology sales drop